Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future...

Area of Science:

• Biotechnology and Regenerative Medicine
• Drug Development and Regulatory Science

Background:

• Extracellular vesicles (EVs) show promise as novel biologics for various therapeutic applications.
• Clinical translation of EV-based therapies is hindered by complex and inconsistent global regulatory frameworks.
• Disparities exist in regulatory guidelines across major jurisdictions like the US, EU, and Asian countries.

Purpose of the Study:

• To systematically analyze and compare regional regulatory guidelines for EV therapeutics.
• To identify critical challenges in quality control, safety, and efficacy assessment for EV products.
• To propose strategies for harmonizing regulations and standardizing analytical methods for EV-based interventions.

Main Methods:

• Systematic review of regional guidelines and strategic frameworks for EV therapeutics.
• Analysis of regulatory hurdles related to EV product characterization, quality control, and safety evaluation.
• Exploration of the direct-to-consumer market implications for EVs and secretome preparations.

Main Results:

• Significant fragmentation and evolution in the regulatory landscape for EV therapeutics globally.
• Key challenges identified in ensuring product consistency, safety, and efficacy due to EV heterogeneity.
• Emerging direct-to-consumer market presents additional regulatory considerations.

Conclusions:

• Harmonizing regulatory requirements is crucial for the advancement of EV-based therapies.
• Standardized analytical approaches and robust quality control measures are essential for product consistency and patient safety.
• Collaborative efforts among regulatory bodies, industry, and academia are vital to accelerate the responsible clinical integration of EV therapeutics.